PatientsVille.com Logo


Pletal Medical Research Studies

Up-to-date List of Pletal Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pletal Medical Research Studies

Rank Status Study
1 Recruiting Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary
Condition: Contraception
Intervention: Drug: Cilostazol
Outcome Measure: Oocyte maturation
2 Unknown  Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety
Condition: Peripheral Artery Disease
Intervention: Drug: Cilostazol, Probucol
Outcome Measures: On the 12-week change in FMD / Safety;   Changes in the biomarker and FMD
3 Recruiting PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Conditions: Brain Ischemia;   Intracranial Hemorrhages
Interventions: Drug: Cilostazol;   Drug: Probucol;   Drug: Aspirin;   Drug: placebo of cilostazol;   Drug: placebo of aspirin;   Device: ankle-brachial index (ABI);   Device: intima-medial thickness (IMT);   Device: new asymptomatic brain hemorrhage;   Device: new ischemic lesions on follow-up FLAIR images
Outcome Measures: time to first occurrence of cerebral hemorrhage;   time to first occurrence of cardiovascular events;   Time to the first occurrence of stroke;   Time to the first occurrence of ischemic stroke;   Time to the first occurrence of myocardial infarction;   Time to the first occurrence of other designated vascular events;   time to occurrence of major bleeding complications;   occurrence of new microbleedings or asymptomatic new hemorrhage on GRE image;   new ischemic lesions on FLAIR images;   change of Ankle-Brachial Index;   change of intima-medial thickness;   time to occurrence of any death
4 Unknown  Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
Conditions: Diabetes Mellitus, Type 2;   Metabolic Syndrome X
Interventions: Drug: cilostazol;   Drug: Placebo
Outcome Measures: The effect on pulse wave velocity (PWV);   the effect on atherosclerotic and inflammatory markers such as adiponectin, hsCRP
5 Recruiting To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject
Condition: Severe Hypercholesterolemia
Intervention: Drug: Atorvastatin, Probucol, Cilostazol
Outcome Measures: the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT);   the additional effect of concomitant administration of Probucol and Cilostazol on mean carotid intima-media thickness (IMT);   the preventive effect of concomitant administration of Probucol and Cilostazol on the incidence of cerebrovascular and cardiovascular events (including intervention);   the effect of concomitant administration of Probucol and Cilostazol on biomarkers;   the safety of Probucol or concomitant administration of Probucol and Cilostazol as determined by physical examination, vital signs, adverse events (AEs), laboratory examinations and 12-lead electrocardiogram (ECGs)
6 Recruiting Cilostazol Stroke Prevention Study for Antiplatelet Combination
Condition: Noncardioembolic Cerebral Infarction
Interventions: Drug: aspirin;   Drug: clopidogrel;   Drug: cilostazol
Outcome Measures: Recurrence of symptomatic ischemic stroke, with the symptoms lasting for at least 24 hours;   Any stroke [ischemic stroke (IS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)];   SAH or ICH;   IS or transient ischemic attack (TIA);   Death from any cause;   Stroke (IS,ICH,SAH), myocardial infarction (MI), or vascular death;   All vascular events: stroke, MI, and other vascular events;   Adverse events and adverse drug reactions;   Severe or life-threatening hemorrhage (GUSTO Criteria)
7 Unknown  Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
Condition: Angioplasty, Transluminal, Percutaneous Coronary
Interventions: Drug: Cilostazol;   Drug: Placebo
Outcome Measures: Major adverse cardiac and cerebrovascular events (MACCEs: composite of death, myocardial infarction, cerebrovascular event, and target vessel revascularization);   Late loss on quantitative coronary angiography;   % neointimal area [100 x (stent area-lumen area)/stent area] on IVUS
8 Unknown  Sufficient Treatment of Peripheral Intervention by Cilostazol
Condition: Arteriosclerosis Obliterans
Intervention: Drug: cilostazol
Outcome Measures: Angiographic restenosis rate;   Cardiovascular events
9 Recruiting Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy
Condition: Hyperlipidemias
Interventions: Drug: HMGCoA reductase inhibitor;   Drug: HMGCoA reductase inhibitor + probucol;   Drug: HMGCA reductase inhibitor + probucol + cilostazol
Outcome Measures: Difference of Carotid artery IMT (mean IMT) between screening and treatment completion(3 years after) or discontinuation;   Time from enrollment date to the onset of composite cerebrovascular events;   Number of composite cerebrovascular and cardiovascular events(including intervention);   The change of Biomarkers(1);   The change of Biomarkers(2);   The change of Biomarkers(3)
10 Unknown  Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism
Conditions: Coronary Artery Stenosis;   Maximal Platelet Aggregation;   Late Platelet Aggregation;   High Post-Treatment Platelet Reactivity
Interventions: Drug: cilostazol;   Drug: clopidogrel;   Drug: aspirin
Outcome Measures: Reduction of maximal platelet aggregation;   Rate of high post-clopidogrel platelet reactivity
11 Recruiting Pharmacodynamic Drug Interaction Between Cilostazol and Statins
Condition: Healthy
Interventions: Drug: C;   Drug: S;   Drug: R
Outcome Measures: lipid lowering effect;   anti-platelet effect
12 Recruiting Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients
Condition: Acute Myocardial Infarction
Intervention: Drug: antiplatelet therapy
Outcome Measures: Major Adverse Cardiovascular and Cerebral Events;   Individual outcome of primary end points, Stent thrombosis,Bleeding Complication,PFT (Platelet function test),Genotyping results
13 Recruiting Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)
Condition: Mild Cognitive Impairment
Interventions: Drug: Aspirin;   Drug: Cilostazol
Outcome Measures: changes in cognitive function;   Number of Participants with Incident cerebral vascular event;   Changes of peripheral inflammatory markers level;   The progression of cerebral white matter lesion and lacunar infarction;   changes in MRI-diffused tension image(DTI)
14 Recruiting Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
Condition: Cerebral Small Vessel Disease
Interventions: Drug: aspirin;   Drug: cilostazol
Outcome Measures: Volume of white matter changes (WMCs);   Mean diffusivity and Fraction Anisotrophy on Diffusion Tensor Imaging;   Number of lacunes;   number of microbleeds;   brain volume and cortical thickness;   Mini-Mental State Examination;   Neurocognitive test;   Clinical Dementia Rating scale;   King's Health Questionnaire;   Geriatric Depression Scale-Short form;   Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI);   Bayer Activities of Daily Living;   Barthel Index;   Pyramidal and Extrapyramidal Scale (PEPS);   Timed UP and Go (TUG) test;   Adverse event
15 Recruiting Safety and Efficacy Study of Cilostazol to Treat Vasapastic Angina
Condition: Vasospastic Angina
Intervention: Drug: Cilostazol
Outcome Measures: Proportion of subjects without chest pain on the final a week/final 2 weeks after 24 weeks treatment.;   secondary 1;   secondary 2;   secondary 3
16 Recruiting Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
Condition: Coronary Artery Disease
Interventions: Drug: Cilostazol;   Drug: Placebo
Outcome Measures: Major Adverse Cardiac and Cerebrovascular Ischemic Events (MACCE);   Major Adverse Cardiac Events (MACE)
17 Recruiting A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
Condition: Vasospastic Angina
Intervention: Drug: Cilostazol
Outcome Measures: Chest Pain Frequency;   Percent change of the chest pain frequency;   Proportion of subjects without chest pain;   total chest pain intensity;   average pain intensity(the total pain intensity/the number of pain);   total nitroglycerin sublingual consumption
18 Recruiting Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
Condition: Coronary Heart Disease
Interventions: Drug: Clopidogrel 75mg;   Drug: Clopidogrel 150mg;   Drug: Aspirin 100mg;   Drug: Cilostazol 100mg
Outcome Measures: Major adverse cardiac and cerebrovascular events;   Secondary endpoint;   bleeding;   quality of life of patient
19 Not yet recruiting Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Cilostazol
Outcome Measures: Inhibition of platelet aggregation (IPA);   Clinical efficacy
20 Recruiting Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)
Condition: Coronary Artery Disease
Interventions: Device: Xience Prime;   Device: Cilotax stent
Outcome Measures: In-segment late luminal loss;   All Death;   Cardiac death;   Myocardial infarction;   Target vessel revascularization (ischemia-driven);   Target lesion revascularization (ischemia-driven);   Stent thrombosis (by ARC definition);   Binary restenosis in both in-stent and in-segment;   Angiographic pattern of restenosis;   Procedural success

These studies may lead to new treatments and are adding insight into Pletal etiology and treatment.

A major focus of Pletal research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Pletal